Rituximab Treatment Outcomes

Pharmacodynamic Effects

The British Journal of Dermatology reports that circulating and tissue-based B cells undergo rapid and sustained depletion that is maintained for at least 6-12 months 1, 3, 4
The American College of Dermatology recommends that rituximab begins depleting circulating B cells within 3 days of administration, but clinical improvement typically becomes evident between 6-11 weeks after treatment initiation, depending on the underlying condition 1, 2

In pemphigus vulgaris, clinical responses occur within 6 weeks of starting rituximab treatment, as reported by the British Journal of Dermatology 2
For Waldenström's macroglobulinemia, rituximab monotherapy shows a duration of response of 8-11 months with standard scheduling and 16-29 months with extended scheduling, according to the Blood journal 6

A transient increase in serum IgM levels occurs in approximately 50% of patients during the first months of treatment, particularly in Waldenström's macroglobulinemia, as noted in the Blood journal 6
B-cell depletion may persist for more than 8-12 months, requiring monitoring for infectious complications, as reported by the American Journal of Kidney Diseases 7
In inflammatory myositis, muscle strength improvement is progressive over 12 weeks following rituximab administration, according to the European League Against Rheumatism 5